Kornimate/medical-research-clean huggingface dataset:
discovering novel cancer treatment options using a comprehensive ngs-based molecular testing panel in the community setting ("dinosaur")

Conditions: Stage III Solid Tumors; Stage IV Solid Tumors

Summary: to prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.


Eligibility criteria:
inclusion criteria: * patients who have given informed consent in accordance with the methods and procedures of this study * diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care * patients who have not received treatment related to his/her cancer * patients who are willing to sign a release of medical records to the research team * male and female patients ≥18 years of age * patients under oncology care of a participating site * sufficient clinical status for collection of biospecimen samples within usual care * patients who have insurance coverage for cmt exclusion criteria: * patients considered minors in the jurisdiction where the protocol is conducted. * patients who are prisoners and pregnant women. * patients who cannot provide consent and did not sign a power of attorney.
covid-19 surveillance and exposure testing in school communities

Conditions: Covid19

Summary: this is a prospective, observational study of covid-19 surveillance and exposure testing in school communities. participating school communities are providing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) tests to students and staff at their schools per school, local, and national guidelines. this study will combine data received from the schools with data collected directly from participants to guide analysis of the co-primary objectives. participants will be grouped into two different cohorts, depending on each school's sars-cov-2 test administration practices. surveillance cohort: schools participating in this cohort will be performing surveillance testing weekly on approximately 10-20% of students and 100% of staff. exposure cohort: schools participating in this cohort will be performing exposure testing on students and staff who have been identified as having close contact with school members diagnosed with sars-cov-2 infection.


Eligibility criteria:
inclusion criteria: * data from all participating school communities will be included in this study (no inclusion/exclusion criteria will be assessed). exclusion criteria: * none
plasma neutrophil gelatinase-associated lipocalin (ngal) as early biomarker for renal dysfunction and good neurologic outcome in out of hospital cardiac arrest patients

Conditions: Post Cardiac Arrest Patient Who Was Treated by Hypothermia Protocol

Summary: postresuscitation disease is a constellation of disorders related to whole-body ischemia and reperfusion syndrome. it includes hypoxic damage in brain, liver, kidney, heart and other organ. in previous study more than one-third of patients resuscitation from out of hospital cardiac arrest developed renal dysfunction. in acute kidney injury, ngal is an earlier marker compared with serum creatinine. cardiac arrest and severe asphyxia result in global brain ischemia. in previous study serum ngal correlated with hypoxic ischemic encephalopathy in asphyxiated neonate. this study was designed to assess serum ngal level in postresuscitative patients to evaluate its relation to hypoxic brain injury severity, and its clinical utility for early detection of acute kidney injury in these patients.


Eligibility criteria:
inclusion criteria: * 19 years and older * successful resuscitation from out of hospital cardiac arrest and spontaneous circulation time is longer than 20 min. * gcs \< 8 exclusion criteria: * pre-existing coma before cardiac arrest * mental change with other cause except cardiac arrest.(ex. traumatic brain injury, cerebro-vascular accident.) * unstable vital sign (systolic blood pressure is lower than 60mmhg) * history of terminal illness. * coagulation deficiency. * pregnancy state or younger than 18 year * pre-existing end-stage renal disease or dependence on renal replacement therapy * transfer to other hospital and cannot know prognosis * withdrawal of care due to family wishes * the patient arrives our hospital after 4 hours or longer from resuscitation. * the patient refuses to sign the consent

Keywords: neutrophil gelatinase-associated lipocalin(ngal) acute renal failure cardiac arrest hypothermia
a study to evaluate the safety of the hiv-1 vaccine mva-b in chronic hiv-1 infected patients successfully treated with haart

Conditions: HIV Infection

Summary: 30 treated chronic hiv-1 infected patients with cd4+ cell counts above 450 cells/ mm3 will be randomized 1:2 to receive placebo (n=10) or vaccine (n=20) at week 0, 4 and 16 and will be observed at the investigation unit of the study site for one hour following vaccination. at week 24 they will stop their haart until the end of the study.


Eligibility criteria:
inclusion criteria: * patient is ≥ 18 years of age; * voluntarily signed informed consent; * patient is male, or female with negative pregnancy test prior to enrolment; * patient has a proven hiv-1 infection (with positive antibodies against hiv-1 and a detectable plasma hiv-1 rna); * patient must be on stable treatment with haart for at least 6 months (haart is defined as an antiretroviral regimen consisting of at least three registered antiretroviral agents\*); * mean of all measured cd4+ cell counts during the 6 months prior to the start of haart must be above or equal to 200 cells/ mm3 * current cd4+ cell count must be at least 450 cells/ mm3; * hiv-rna must be below 50 copies/ ml for the last 6 months prior to inclusion, during at least two measurements (occasional so called 'blips' up to 50 copies/ml are permitted); * patient is one of the following: not sexually active, or a heterosexually active female, agreeing to use condoms with her partner from 14 days prior to the first vaccination until 4 months after the last, even though using another method of contraception, and willing to undergo pregnancy tests during screening and prior to each vaccination, or a male, agreeing to use condoms with his partner from the day of the first vaccination until 4 months after the last vaccination. exclusion criteria: * treatment with a non-haart regimen of antiretroviral agents prior to the start of haart; * history of a cdc class c event (see appendix); * interruption of haart during the course of the study which is expected at the time of inclusion; * history of exposure \<20 years ago to any poxvirus based vaccine; * patient is female and has a positive pregnancy test or the wish of pregnancy: * active opportunistic infection, or any active infection or malignancy within 30 days prior to screening visit; * therapy with immunomodulatory agents, including cytokines (e.g. il2) and gamma globulin, or cytostatic chemotherapy within 90 days prior to screening visit; * history of allergy to any vaccine component; * use of anti-coagulant medication; * use of any investigational drug during the 90 days prior to study entry; * previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy * any other condition which, in the opinion

Keywords: hiv seronegativity hiv preventive vaccine
knowledge, beliefs and attitudes of greek physiotherapist about pain neuroscience education

Conditions: Chronic Musculoskeletal Pain

Summary: an e-survey study will be carried out based on checklist for reporting results of 52 internet e-surveys (cherries)". the purpose of this study is to investigate the knowledge, beliefs and behaviour of greek physiotherapists regarding the pain neuroscience education program (pne) as an intervention in patients with chronic musculoskeletal pain.

the main questions it aims to answer are: what physiotherapists know about a pne program; what physiotherapists believe about the using of a pne program in patients with chronic musculoskeletal pain? whether and how often they use a pne program in patients with chronic musculoskeletal pain? what are the barriers of using pne in patients with chronic musculoskeletal pain?

Eligibility criteria:
inclusion criteria: * physiotherapists who are member of panhellenic association of physiotherapist in greece, with active clinical practice in greece and clinical experience in musculoskeletal disorders (\>12 months). exclusion criteria: * none

Keywords: pain neuroscience education chronic musculoskeletal pain
the utility of pet/ct in the planning of stereotactic body radiotherapy for non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the trial evaluates the utility of 18fdg-pet/ct scan in the target definition process when sbrt is planned for stage i nsclc.

the trial aims to evaluate the utility of 18fdg-pet/ct in sbrt planning for nsclc with particular emphasis on the definition of macroscopic and microscopic boundaries of malignant growth. studies indicate that the definition of the gross tumor volume may gain in quality when ct and 18fdg-pet are combined. in about 30-60% of nsclc patients considered for radiotherapy, alteration of ct-based treatment volumes is the consequence of a supplementary 18fdg-pet scan. studies examining the effect of combined pet/ct scans on the delineation of the gtv generally show reduced intra- and inter-clinician variability. whether this higher degree of consistency is an actual improvement remains to be proven. pathological specimens from operated nsclc patients may serve as a gold standard in this respect. to meet the need for tight margins, the clinical target volume in sbrt planning is generally presumed to correspond to the gtv. whether this clinical practice rests on firm ground is also an issue that can be addressed in a pet-ct-pathology correlation study.

Eligibility criteria:
inclusion criteria: * age 18 years or above * histologically or cytologically verified nsclc * disease stage i (t1-2 n0 m0) * referred from the multi-disciplinary lung cancer conference at aarhus university hospital for operation at skejby hospital, aarhus university hospital * oral and written informed consent exclusion criteria: * medically treated diabetes mellitus * fasting blood-glucoses above 6,7 mm * blood-creatinin above normal * allergies to intravenous contrast * detention according to the danish laws on psychiatrics that does not comply with participation in a clinical trial * employment at the dept. of oncology, aarhus university hospital * pregnancy * lactation
german colon capsule registry

Conditions: Colon Cancer; Colon Polyp; Diarrhea; Inflammatory Bowel System; Ulcerative Colitis

Summary: aim of the registry is to evaluate all colon capsule endoscopies performed in germany. this is to investigate safety, quality assurance and quality control of colon capsule endoscopy.

colon capsule endoscopy (cce, pill cam colon 2, (given imaging ltd, yoqneam, israel and given imaging emea, hamburg, germany) provides direct visualization of the colon mucosa, enabling the investigator to diagnose colonic disease. cce is a complementary means to flexible ileo-colonoscopy andt safety, quality assurance and quality control of cce is not well understood. there are about 15 000 investigations performed worldwide until now, but systematic data on performance in a community based setting are lacking. this study aims to investigate safety, quality assurance and quality control of colon capsule endoscopy.

Eligibility criteria:
inclusion criteria: * indication for colon capsule endoscopy * age of 18 years or older * consent of the patient exclusion criteria: * intestinal obstruction * dyphagia * pregnancy

Keywords: colon capsule endoscopy colonoscopy screening colonoscopy
telenutrition center: examining the implementation of behavioral therapy for obesity

Conditions: Obesity

Summary: the telenutrition center will use the reach, effectiveness, adoption, implementation and maintenance (re-aim) framework to assess the implementation of an evidence-based, intensive behavior therapy (ibt) for obesity intervention (with a motivational interviewing \[mi\] framework) based on the centers for medicaid and medicare services (cms) ibt for obesity benefit. the intervention will be examined under real-world conditions with technology supplementation to address obesity and related chronic disease among young adult (18-50 years of age) african americans across the state. the intervention contact will model the cms ibt for obesity benefit according to the patient contact schedule (of weekly visits in the first month, biweekly in months 2-7, and once a month per months 8-12) and include nutrition, stage of change and other physical and psychosocial assessments. program delivery will be assisted by the "bridge2u" web and mobile platform and supported in both clinic and community settings. the proposed project will shed new light on how ibt for obesity (and similar) models may be amended to facilitate the provision of health care resources in areas with limited to no resources, such as the state of mississippi.


Eligibility criteria:
inclusion criteria: * body mass index \>/=28 * 25 to 50 years of age * history or risk of preventable co-morbidities (ie. diabetes, hypertension, and/or dyslipidemia) exclusion criteria: * body mass index \<28 * \<25 years of age * \>50 years of age * no history or risk of preventable obesity comorbidities * any disease diagnosis (ie. cancer) where weight loss is contraindicated
influence of hygiene-dietetic habits and treatment adherence on the effectiveness of the gastroesophageal reflux illness treatment with rabeprazol

Conditions: Gastroesophageal Reflux

Summary: the objective of this observational study is to evaluate hygiene-dietetic habits as co-adjuvant treatment of the pharmacologic therapy use to treat gastroesophageal reflux.

gastroesophageal reflux illness is a multifactor pathology with a common mechanism: a prolonged exposure of the esophageal mucosa to the gastric solutions. modification of the life style and the hygiene-dietetic habits are frequently recommended as an initial therapeutic instrument in gastroesophageal reflux pathology. but there is not agreement about the effectiveness of these habits in the improvement of the illness. different clinical practice guidances have shown contradictions in the effectiveness of changing hygiene-dietetics habits of the life style. the high effectiveness of the new pharmacologic treatment in gastroesophageal reflux pathology make it necessary to review the role of hygiene-dietetic habits in this illness. proton pump inhibitors (ppi) act in the final step of the gastric secretion. ppi's block atp-ase h+/k+ in gastric parietals cells. this mechanism generates a higher acid inhibition, longer than the inhibition produced by h2-receptor antagonists. it has been described that inhibition of acid secretion has produced a recovery of the gastroesophageal pathology in a high percentage of the patients resistant to conventional drugs. this is an observational, multicenter, open and prospective study. the primary objective is to evaluate hygiene-dietetic habits as co-adjuvant of rabeprazol treatment in gastroesophageal reflux . it is expected to include 570 patients with gastroesophageal pathology erosive or non-erosive and acute or chronic treated with rabeprazol per clinical practice, 20mg per day, orally, for 8 weeks. all data collected will be prospective and will include the following: demographic data, progress of the pathology, change of hygiene-dietetic habits, treatment adherence, concomitant treatments and adverse events. observational study - no investigational drug administered

Eligibility criteria:
inclusion criteria: * patients with gastroesophageal pathology erosive or non-erosive and acute or chronic treated with rabeprazol per clinical practice exclusion criteria: * patients pregnant or lactating * other gastrointestinal pathologies * intestinal or gastric survey * other severe concomitant pathologies * drug abuse or use of nsais (non-steroidal anti-inflammatories) more than 3 days/week

Keywords: gastroesophageal reflux rabeprazole
a study with abl103 in subjects with advanced or metastatic solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a first-in-human phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of abl103 to evaluate the safety, tolerability, mtd (maximum tolerated dose) and/or rp2d (recommended phase 2 dose), pharmacokinetics, immunogenicity, preliminary antitumor activity of abl103 in subjects with any progressive locally advanced(unresectable) or metastatic solid tumor who are relapsed or refractory following the last line of treatment and have no available standard of care option. this study includes 2 parts: a dose-escalation part and tumor-expansion part


Eligibility criteria:
inclusion criteria: * subject must understand and be willing to provide informed consent and be able to comply with the study procedures and restrictions. * subject must be ≥18 years of age on the day of signing the informed consent form (icf) * subject must have a histologically confirmed locally advanced unresectable, or metastatic solid tumor. * subject must be relapsed or be refractory to available standard therapy or they must be intolerant of available standard therapy. * subject must meet eastern cooperative oncology group (ecog) performance status 0 or 1. * subject must have an estimated life expectancy of at least 12 weeks. * subjects must be recovered from aes from prior therapy to grade 1 or the baseline grade more than 14 days prior to the first administration of the study drug, except alopecia or grade 2 toxicities that are deemed stable or irreversible (eg, peripheral neuropathy) * subjects must have adequate hematologic, renal, hepatic, and thyroid functions confirmed based on the screening laboratory test within 7 days prior to the first administration of abl103. exclusion criteria: * subject has received prior anticancer monoclonal antibody treatment or investigational therapy within 28 days prior to the first administration of study drug. * subject has received prior chemotherapy or radiation therapy within 2 weeks or targeted small molecule therapy within 5 half-lives prior to the first administration of study drug. * subject requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study drug administration. * subject has a history of drug-induced pneumonitis (interstitial lung disease) or currently has pneumonitis. * subject has risk factors for bowel obstruction or bowel perforation, including, but not limited to a history of acute diverticulitis, intra-abdominal abscess, and abdominal carcinomatosis. * subject discontinued from prior immunomodulatory therapy due to any intolerable immune-related adverse events (iraes) requiring systemic steroid treatment. * subject has received prior treatment with anti-b7-h4 antibody and/or anti-4-1bb antibody.
the art of waiting: evaluation of an interactive media experience in a children's hospital clinic waiting space

Conditions: Anxiety

Summary: the purpose of this study is to test the hypothesis that providing low-intensity opportunities for interactive play can improve the waiting and overall clinic experiences of children. this study evaluates an innovative, interactive system called screenplay designed to realize the intentions of the "healing environment" in the waiting space of a paediatric hospital.

existing entertainment and distraction options (e.g. toys, video games) meet neither organizational standards nor families' needs with respect to accessibility and infection control. additionally, they do not provide the types of positive experiences (e.g. calm, low intensity) that are most desirable for children awaiting treatment. the goal of this research is to empirically evaluate the effectiveness of screenplay, a technology that enables users to create or manipulate animations on a screen/projection, and to provide an evidence-informed model for the design of optimal paediatric waiting spaces. a blinded, clustered, parallel randomized controlled trial applying objective outcome measures and qualitative methods will be used to compare children allocated to one of three waiting conditions at a large urban rehabilitation hospital: (a) no media (standard care), (b) passive media (a silent nature video), or (c) interactive media (screenplay). this study will answer the questions: can interactive media (i.e. screenplay): 1. reduce state anxiety in children/youth attending an outpatient clinic? and, 2. improve child, parent, and staff satisfaction with the clinic experience? we hypothesize that: 1. decreases in state anxiety will be greater for children exposed to screenplay for 10 minutes than for those exposed to passive (i.e. a nature video) or no media (i.e. standard care/control). the decrease in state anxiety associated with screenplay will be \>5 points on the normalized 100 point state anxiety scale. 2. screenplay will generate more movement/activity on the floor (i.e. an indicator of active engagement with the system) than the passive media or control conditions as measured via contact floor sensors. 3. the waiting and overall clinic experience of children with diverse mobility, parents, and staff will be perceived more positively when exposed to screenplay as compared to passive media or control conditions.

Eligibility criteria:
participants include clients, their parents/guardians, and staff associated with the outpatient clinic at holland bloorview kids rehabilitation hospital. 1. children and youth aged 5 to 19 years and their guardian/parent. 2. anticipated wait time ≥30 minutes to allow time to complete the study. 3. ability to communicate in english through speech, writing/typing, or other communication device. note: for children who cannot communicate their thoughts/feelings, parent-proxy may be used. 4. all outpatient clinic staff

Keywords: hospital design technology anxiety